The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Nephrology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Transpl Int. 2019 Sep;32(9):918-932. doi: 10.1111/tri.13413. Epub 2019 Mar 28.
Patient selection for combined liver-kidney transplantation (CLKT) is a current issue on the background of organ shortage. This study aimed to compare outcomes and post-transplant renal function for patients receiving CLKT and liver transplantation alone (LTA) based on native renal function using estimated glomerular filtration rate (eGFR) stratification. Using the UK National transplant database (NHSBT) 6035 patients receiving a LTA (N = 5912; 98%) or CLKT (N = 123; 2%) [2001-2013] were analysed, and stratified by KDIGO stages of eGFR at transplant (eGFR group-strata). There was no difference in patient/graft survival between LTA and CLKT in eGFR group-strata (P > 0.05). Of 377 patients undergoing renal replacement therapy (RRT) at time of transplantation, 305 (81%) and 72 (19%) patients received LTA and CLKT respectively. A significantly greater proportion of CLKT patients had severe end-stage renal disease (eGFR < 30 ml/min/1.73 m ) at 1 year post-transplant compared to LTA (9.5% vs. 5.7%, P = 0.001). Patient and graft survival benefit for patients on RRT at transplantation was favouring CLKT versus LTA (P = 0.038 and P = 0.018, respectively) but the renal function of the long-term survivors was not superior following CLKT. The data does not support CLKT approach based on eGFR alone, and the advantage of CLKT appear to benefit only those who are on established RRT at the time of transplant.
患者选择进行肝-肾联合移植(CLKT)是在器官短缺背景下的一个当前问题。本研究旨在根据肾小球滤过率(eGFR)分层,比较基于供体肾固有功能的接受 CLKT 和单独肝移植(LTA)的患者的结局和移植后肾功能。使用英国国家移植数据库(NHSBT),分析了 6035 例接受 LTA(N=5912;98%)或 CLKT(N=123;2%)[2001-2013]的患者,并根据移植时 eGFR(eGFR 组分层)的 KDIGO 分期进行分层。在 eGFR 组分层中,LTA 和 CLKT 之间的患者/移植物存活率没有差异(P>0.05)。在接受移植时进行肾脏替代治疗(RRT)的 377 例患者中,分别有 305(81%)和 72(19%)例患者接受了 LTA 和 CLKT。与 LTA 相比,CLKT 患者在移植后 1 年有更高比例的严重终末期肾病(eGFR<30 ml/min/1.73 m )(9.5%比 5.7%,P=0.001)。在移植时接受 RRT 的患者中,CLKT 相对于 LTA 具有明显的患者和移植物存活率优势(P=0.038 和 P=0.018),但长期存活者的肾功能并没有因 CLKT 而更好。数据不支持仅基于 eGFR 进行 CLKT 方法,CLKT 的优势似乎仅受益于那些在移植时已经接受既定 RRT 的患者。